Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProHema-CB in pediatric inherited metabolic disorders
NCT02354443Phase 1Terminated
- Sponsor
- Fate Therapeutics
- Start
- Jun 2015
- Primary completion
- Dec 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ProHema in inherited metabolic disorders (IMD), sponsored by Fate Therapeutics. Primary endpoint: Safety Profile, Assessed Primarily by Neutrophil Engraftment at Day 42. Started Jun 2015; status: terminated.
02
Drugs
ProHema
03
Conditions
inherited metabolic disorders (IMD)
Beyond the preview
Go deeper on NCT02354443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354443.